Sapna Yadavilli
About
Sapna Yadavilli is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Sapna Yadavilli has authored 19 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 6 papers in Immunology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Sapna Yadavilli's work include Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (10 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Sapna Yadavilli is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (10 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Sapna Yadavilli collaborates with scholars based in United States, France and Australia. Sapna Yadavilli's co-authors include James Smothers, Patrick A. Mayes, Axel Hoos, Hong Shi, Shuyun Zhang, Laura Seestaller‐Wehr, Tianqian Zhang, Chris Hopson, Lyuben Tsvetkov and Stephen D. Eastman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
In The Last Decade
Sapna Yadavilli
17 papers receiving 450 citations
Peers
Sapna Yadavilli
Viviana Bozón United States
Chris Hopson United States
Maria Amann Switzerland
Nikolaos Ioannou United Kingdom
Blanca Homet United States
Shinichiro Izawa Japan
Patrick Chun United States
Sheera R. Rosenbaum United States
Antonio Gnoni Italy
H-T. Arkenau United Kingdom
Citations per year, relative to Sapna Yadavilli Sapna Yadavilli (= 1×)
peers
Viviana Bozón
Countries citing papers authored by Sapna Yadavilli
Since
Specialization
Citations
This map shows the geographic impact of Sapna Yadavilli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sapna Yadavilli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sapna Yadavilli more than expected).
Fields of papers citing papers by Sapna Yadavilli
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sapna Yadavilli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sapna Yadavilli. The network helps show where Sapna Yadavilli may publish in the future.
Co-authorship network of co-authors of Sapna Yadavilli
This figure shows the co-authorship network connecting the top 25 collaborators of Sapna Yadavilli. A scholar is included among the top collaborators of Sapna Yadavilli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sapna Yadavilli. Sapna Yadavilli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Maio, Michele, Víctor Moreno, Juan Martín-Liberal, et al.. (2025). First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 13(8). e011475–e011475.
2.
Perrin, Jessica, Frank Wippich, Jeremy D. Waight, et al.. (2023). Abstract 6647: Dostarlimab shows dose-dependent immune activation of the tumor microenvironment in a patient-derived NSCLC explant model similar to pembrolizumab. Cancer Research. 83(7_Supplement). 6647–6647.
3.
Conner, Michael, et al.. (2022). Emergence of the CD226 Axis in Cancer Immunotherapy. Frontiers in Immunology. 13. 914406–914406.
4.
Maio, Michele, Jeffrey S. Weber, María Vieito, et al.. (2021). Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC). Cancer Research. 81(13_Supplement). CT033–CT033.
5.
Angevin, Eric, Stefanie L. Groenland, Todd M. Bauer, et al.. (2020). 11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study. Annals of Oncology. 31. S3–S3.
6.
Hansen, Aaron R., Min Hee Hong, Ezra E.W. Cohen, et al.. (2020). INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology. 38(15_suppl). TPS6591–TPS6591.
7.
Waight, Jeremy D., Meixia Bi, David Kilian, et al.. (2020). Abstract 2220: Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies. Cancer Research. 80(16_Supplement). 2220–2220.
8.
Massarelli, Erminia, Ani Sarkis Balmanoukian, María Vieito, et al.. (2020). INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 6544–6544.
9.
Maio, Michele, Stefanie L. Groenland, Todd M. Bauer, et al.. (2019). Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study. Annals of Oncology. 30. v793–v793.
10.
Hansen, Aaron R., Naiyer A. Rizvi, John Hilton, et al.. (2019). Abstract CT166: A Phase I/II, open-label, two part study of GSK3359609 in combination with tremelimumab in participants with selected, advanced solid tumors. Cancer Research. 79(13_Supplement). CT166–CT166.
11.
Coutzac, Clélia, Aurore Vozy, Marc Ballas, et al.. (2019). Abstract 2268: Agonistic T cell non depleting ICOS antibody strongly enhances anti-tumor activity with CTLA4 blocking monoclonal antibody without exacerbating colitis. Cancer Research. 79(13_Supplement). 2268–2268.
12.
Coutzac, Clélia, Aurore Vozy, Marc Ballas, et al.. (2019). Abstract 2268: Agonistic T cell non depleting ICOS antibody strongly enhances anti-tumor activity with CTLA4 blocking monoclonal antibody without exacerbating colitis. Immunology. 2268–2268.
13.
Brett, Sara, Sapna Yadavilli, Laura Seestaller‐Wehr, et al.. (2018). Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. Annals of Oncology. 29. viii652–viii653.
14.
Amé-Thomas, Patricia, Karin Tarte, Françoise Gondois‐Rey, et al.. (2018). CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas. Blood Advances. 2(15). 1889–1900.
15.
Hansen, Aaron R., Todd M. Bauer, Víctor Moreno, et al.. (2018). First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1. Annals of Oncology. 29. viii404–viii404.
16.
Angevin, Eric, Todd M. Bauer, Catherine Ellis, et al.. (2017). Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors. Cancer Research. 77(13_Supplement). CT039–CT039.
17.
Yadavilli, Sapna, Tianqian Zhang, Ashleigh Hahn, et al.. (2017). Abstract 1637: ICOS agonism induces potent immune activation and anti-tumor response in non-clinical models. Cancer Research. 77(13_Supplement). 1637–1637.
18.
Angevin, Eric, Mary S. Barnette, Todd M. Bauer, et al.. (2017). INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). TPS3113–TPS3113.
19.
Liu, Li, Patrick A. Mayes, Stephen D. Eastman, et al.. (2015). The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clinical Cancer Research. 21(7). 1639–1651.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Viviana Bozón Breakdown of academic impact, for papers by Chris Hopson Breakdown of academic impact, for papers by Maria Amann Breakdown of academic impact, for papers by Nikolaos Ioannou Breakdown of academic impact, for papers by Blanca Homet Breakdown of academic impact, for papers by Shinichiro Izawa Breakdown of academic impact, for papers by Patrick Chun Breakdown of academic impact, for papers by Sheera R. Rosenbaum Breakdown of academic impact, for papers by Antonio Gnoni Breakdown of academic impact, for papers by H-T. Arkenau